Equity Overview
Price & Market Data
Price: $1.90
Daily Change: $0.00 / 0.00%
Range: $0 - $0
Market Cap: $23,175,440
Volume: 0
Performance Metrics
1 Week: -5.71%
1 Month: -12.84%
3 Months: -44.77%
6 Months: -96.10%
1 Year: -91.55%
YTD: -44.77%
Company Details
Employees: 42
Sector: Health technology
Industry: Biotechnology
Country: United States
Details
Q32 Bio Inc., a clinical-stage biotechnology company, develops novel biologics to restore healthy immune balance in patients with autoimmune and inflammatory diseases driven by pathological immune dysfunction. The company is developing Bempikibart (ADX-914), a fully human antiinterleukin-7 receptor alpha antagonist monoclonal antibody designed to re-regulate adaptive immune function by blocking signaling mediated by interleukin-7 and thymic stromal lymphopoietin for the treatment of atopic dermatitis and alopecia areata. It also develops ADX-096, a C3d mAb CR1 fusion protein for use in ophthalmologic indications, as well as other C3d mAb fusions and nanobodies designed for tissue-targeted complement inhibition. The company was founded in 2017 and is based in Waltham, Massachusetts.